
building sci-fi health scans @neko // prev: @amoamoamo and @zenly ☘️ via Paris & NYC
London
Joined October 2013
- Tweets9.4K
- Following1.2K
- Followers7.5K
- Likes26.6K
sarah mcbride retweeted
Got Neko’d in NYC and learned more about my body in an hour than i have in years
They scan you head to toe, take thousands of pictures of your skin, run bloodwork and measure things i wouldn't have even thought to ask about. Then you get to see a 3D version of your body (surreal lol) and sit down with a doctor who explains what everything means, from what's looking good today to what to pay attention to for the future
We’ve gotten really good at tracking our steps, sleep, calories, etc. But I’m much more excited about technology that helps us understand our bodies before there's something wrong!!
Very very into this future of preventative, personalized healthcare and living healthier for longer. More of this pls
sarah mcbride retweeted
What’s the hardest reservation in NYC right now, a prime time table at The Corner Store or a visit to @Neko?
3rd annual @Neko checkup & it keeps getting better and better.
They set the bar for what consumer healthcare should feel like.
Had my second @neko checkup today. Weirdly, was almost looking forward to it.
I'm not a doctor but the entire user experience is something I've never experienced at any healthcare related facility (public/private).
Rebooked for next year + used almost all my referrals. Afaik I get nothing from giving out my referral codes. Have one left, just DM!
sarah mcbride retweeted
We are - but imagine if you re-built the entire data acqusition approach in retinal imaging to capture 100x the amount of information to go much much deeper. That's what we're building, excited to show it to you next year.
sarah mcbride retweeted
This is a very exciting potential new treatment for food allergies! But to appreciate just how remarkable this development is, let me share a personal story about Xolair, the anti-IgE antibody currently used to treat allergies, and how painfully slow biomedical progress has been until now. I believe AI is about to change this dramatically!
Back in 1989, 37 years ago, I was a visiting medical student as an intern at Ciba-Geigy immunology laboratories (which later became part of Novartis) in Basel, Switzerland. In the immunology department where I was working, one of the scientists, Christoph Heusser, had proposed developing antibodies against IgE, the molecule responsible for triggering allergic reactions, back in 1986!
Around the same time, scientists at a small biotech company called Tanox had independently developed a promising anti-IgE antibody. Ciba-Geigy and Tanox subsequently formed a partnership in 1990 to advance this approach.
I still remember the excitement surrounding this research as vividly as if it were yesterday! Imagining the possibility of treating allergies by targeting a single molecule responsible for triggering the entire allergic response was extremely novel back than. I was fortunate enough to witness the early development of this revolutionary idea firsthand, and it was incredibly exciting!
But here is where the story becomes rather astonishing.
Genentech subsequently developed a similar antibody in 1993, and the three companies eventually joined forces. Their collaboration led to Xolair (omalizumab), which finally received FDA approval in 2003, 17 years after the original concept! And that approval was initially for allergic asthma. It took another 21 years, until 2024, for Xolair to receive approval specifically for food allergies!
Think about that. Almost 40 years after those original discoveries, Xolair remains the only FDA-approved anti-IgE antibody for food allergies. That is how painfully slow the traditional process of developing new medicines has been!
Now compare that timeline with what Claude and Divergence Labs have accomplished in approximately ONE MONTH!
Claude generated roughly 35,000 antibody designs, helping identify promising candidates that could potentially remove IgE already attached to immune cells. This could be a major advance over Xolair, which primarily neutralizes free IgE. Some of these new antibody designs already performed better than Xolair in specific laboratory tests!
Of course, these are still early experimental results. The complete therapeutic antibody needs to be developed, validated, and eventually tested in clinical trials.
But consider the implications!
We are witnessing the beginnings of a fundamental transformation in biomedical research. As AI intelligence continues to advance exponentially, combined with automated laboratories, virtual cells, and eventually patient digital twins, I believe we will compress decades of drug discovery into months or even weeks!
Clinical trials and regulatory approval will also become much faster as AI improves our ability to predict efficacy, toxicity, and treatment responses.
My prediction is that instead of waiting decades for individual breakthrough medicines, we will eventually be developing hundreds, perhaps thousands, of new treatments in parallel, within just a few years!
Having personally witnessed the beginnings of anti-IgE antibody development nearly four decades ago, and now seeing AI begin to revolutionize that very same field, makes this moment extraordinarily exciting for me.
I have been waiting for this transformation for most of my scientific career. And I believe we are finally entering the era when the pace of medical discovery will accelerate beyond anything we have experienced in human history!
Today, in collaboration with Anthropic, we’re excited to share rapid initial progress towards an antibody treatment for food allergy, which affects over 200 million people worldwide, discovered with the help of Claude.
At Divergence Labs, we believe that AI can unlock the next generation of antibody therapeutics with more effective mechanisms than before. Such mechanisms are urgently needed in food allergy, which involve overcoming one of the tightest affinity protein pairs in immunology, IgE and its receptor FcεRI, on mast cells.
Treatment with Xolair—the only approved antibody for food allergy—sequesters circulating IgE, but mast cells remain sensitized for weeks to months due to the extraordinarily slow dissociation of IgE from FcεRI.
We envision a treatment that actively pulls IgE off of FcεRI, without waiting for natural dissociation. Like picking a lock, this requires the right combination of geometry and force.
Our research team, working with Claude, ideated on mechanisms to accomplish this disruption, and converged on an antibody format with two arms with different functions and epitopes. Within one month, we designed, synthesized, and experimentally confirmed the biophysical function of the two arms, which we are now assembling into full therapeutic formats.
sarah mcbride retweeted
Today, in collaboration with Anthropic, we’re excited to share rapid initial progress towards an antibody treatment for food allergy, which affects over 200 million people worldwide, discovered with the help of Claude.
At Divergence Labs, we believe that AI can unlock the next generation of antibody therapeutics with more effective mechanisms than before. Such mechanisms are urgently needed in food allergy, which involve overcoming one of the tightest affinity protein pairs in immunology, IgE and its receptor FcεRI, on mast cells.
Treatment with Xolair—the only approved antibody for food allergy—sequesters circulating IgE, but mast cells remain sensitized for weeks to months due to the extraordinarily slow dissociation of IgE from FcεRI.
We envision a treatment that actively pulls IgE off of FcεRI, without waiting for natural dissociation. Like picking a lock, this requires the right combination of geometry and force.
Our research team, working with Claude, ideated on mechanisms to accomplish this disruption, and converged on an antibody format with two arms with different functions and epitopes. Within one month, we designed, synthesized, and experimentally confirmed the biophysical function of the two arms, which we are now assembling into full therapeutic formats.
sarah mcbride retweeted
News
@_CommonMagic (population: 1) is doubling in size
I'm hiring a London based operating partner to run the machine behind the fund, systems to events to network
Come join: buildthemachine.commonmagic.…
Bonus points if you find the microsite's easter egg
sarah mcbride retweeted
When we launched @Neko in the UK two years ago, it took us 10 months before expanding to our second city.
The US demands a whole new pace of execution.
Just three months after launching our first US clinic in NYC, we’re bringing Neko to Miami.
This location is very different from anything we’ve done before! Sharing more soon.
sarah mcbride retweeted
See you December 9th, Miami ☀️
Our second US clinic is opening at Aventura Mall.
The waitlist is already growing. Join now to secure your spot.
sarah mcbride retweeted
Now that we've cracked Navier-Stokes and flying cars, there is only one true, super-human technological challenge left - lowering British electricity bills.
And Fuse seem to have cracked it! An affordable home battery & solar system which means lower bills and more energy independence at home, and at scale more capacity on the grid.
Hi there Jules, another impressive release from @alanchanguk , @charlesorr and the phenomenal team @fuseenergy.
Meet Jules by Fuse Energy.
An intelligent energy system for your home. Plug in and autopilot does the rest.
It learns your habits, stores power, trades the excess and continuously lowers your bills.
Solar and storage is now for everyone.
Energy intelligently designed for you.
Up to £330 a year off your bills.
Reservations now open
sarah mcbride retweeted
“The science of prevention is pretty clear.”
–@HjalmarNilsonne, CEO of @Neko Health
At $7B startup Neko, Nilson believes that society can save more money by investing in preventive care, versus waiting for things to go wrong with your health.
“I think over time we’re going to see that these things are no-brainers, that of course everyone should be able to have high-quality preventive services that they can do every year to stay away from the worst outcomes. And if you do that, you just save a lot of money in the system overall.”
Still, he knows Neko can’t change the global healthcare system overnight.
“It’s going to take us a while to get there. The good news is that the world is a pretty big place, so we don’t need to have everybody in the world doing this at the same time.”
Watch the full episode here: youtu.be/lpe-6Ias6xQ
about time some whimsy (and good product design) was brought to the home energy category !!
Meet Jules by Fuse Energy.
An intelligent energy system for your home. Plug in and autopilot does the rest.
It learns your habits, stores power, trades the excess and continuously lowers your bills.
Solar and storage is now for everyone.
Energy intelligently designed for you.
Up to £330 a year off your bills.
Reservations now open
1
14
1,034
sarah mcbride retweeted
it’s me katniss everdeen from district 12 getting my @Neko scan
sarah mcbride retweeted
Loved chatting with @alexrkonrad about tough times, running a moonshot in stealth for almost 5 years and what's next for Neko after NY
Neko CEO Hjalmar Nilsonne was licking his wounds after "crash landing" a climate startup. Then he got a fateful DM from Spotify's Daniel Ek
Together, @HjalmarNilsonne and @eldsjal co-founded @Neko, a $7B startup that calls itself "the most valuable hour you can spend on your health."
After years operating in Europe, Neko recently launched in NYC, where it's quickly built a waitlist of 50,000 people, and started work on 3 more locations. Miami, San Francisco and Washington, D.C. are next.
“People sometimes think that there’s some machine, and you go in, and you get a kind of paper receipt telling you if you’re gonna die or not,” Hjalmar tells me. “In reality, it’s the exact opposite.”
On The Upstarts Podcast, Nilsonne talks about the fateful Twitter DM from Ek that got Neko going; why the doctor visit hasn’t changed much in 100 years; and how to keep a startup team motivated while chasing a long-term “moonshot.”
Plus, he shares his Upstart Moment: a bet-the-company pivot driven by an internal memo he wrote, “Free Is Not Enough.”
A big thanks to this season's sponsors @Atlassian and @chargebee for supporting unfiltered founder interviews like this 🫡
CHAPTERS:
00:00 Introduction
01:48 Mapping Your Body In One Hour
03:54 Why The Doctor’s Visit Hasn’t Changed In 100 Years
07:31 Building Four Businesses In One: Devices, Hardware, Software, Clinics
09:22 Breaking Down A Neko Visit First-Hand
12:58 Why Half of Neko’s U.K. Members Never Had A Health Check
16:59 ‘Brutally Efficient With Your Time’: Why Every Second Counts
19:04 Helping Human Doctors, Not Replacing Them
22:40 Delivering Outcomes For the 92% Of Members Not At Risk
26:47 A Climate ‘Crash Landing’ And A DM From Daniel Ek
33:12 Motivating A Team To Chase A Moonshot
37:42 Neko’s Upstart Moment: The ‘Free Is Not Enough’ Memo And Pivot
41:30 Pricing Neko Accessibly For The 99.9%
45:44 What The Tesla Roadster Can Teach Founders About Change
48:33 Space-Age Scan, Old-School Advice: Cut The Coffee
Thanks for watching!
sarah mcbride retweeted
“We're trying to be brutally efficient with your time.”
At @Neko Health, CEO @HjalmarNilsonne is “obsessed” with saving members time in their preventive health visits and results – down to the second.
“ We used to have one of my colleagues, Linda, she would literally have a notepad, and we would go over the scan again. And I would yell like, ‘What time do we have?’ And she would be like, ‘It's 13:57.’ And I went, ‘Ah, it's 10 seconds too long.’”
Neko staff practiced speeding up the process to the right balance between efficiency and quality. “When you’re in there, we don’t want you to feel like you’re a hamburger in McDonald’s,” Nilsonne says.
Catch the full episode on The Upstarts Podcast, presented by @atlassian and @chargebee.
Watch the whole episode here: youtu.be/lpe-6Ias6xQ




































